recombinant murine il-33 (ril-33; carrier-free  (R&D Systems)

Journal: Inflammation

Article Title: Interleukin-33 Promotes Neutrophil Extracellular Trap Formation To Aggravate Renal Ischemia-Reperfusion Injury Through ST2/PI3K/Akt and ST2/PAD4 Pathways

doi: 10.1007/s10753-025-02364-8

Figure Lengend Snippet: IL-33 was upregulated and positively correlated with NET formation in renal transplant patients. ( A ) Paired analysis of serum IL-33 levels, ( B ) paired analysis of serum MPO-DNA levels, ( C ) paired analysis of serum citH3 levels in renal transplant patients preoperatively and postoperatively ( n = 20). ( D ) Correlation analysis for postoperative serum IL-33 level and serum MPO-DNA level (Spearman r = 0.6892, P = 0.0008). ( E ) Correlation analysis of postoperative serum IL-33 level and serum citH3 level (Spearman r = 0.6486, P = 0.002). * P < 0.05, ** P < 0.01

Article Snippet: Mice were intraperitoneally injected with recombinant IL-33 (rIL-33) (10ug per mouse, MedChemExpress, America) or PBS immediately following exposure to renal ischemia.

Techniques:

Journal: Inflammation

Article Title: Interleukin-33 Promotes Neutrophil Extracellular Trap Formation To Aggravate Renal Ischemia-Reperfusion Injury Through ST2/PI3K/Akt and ST2/PAD4 Pathways

doi: 10.1007/s10753-025-02364-8

Figure Lengend Snippet: IL-33 and NETs were elevated following renal I/R in mice. ( A - B ) Serum IL-33 levels ( A ) and renal tissue homogenate IL-33 levels ( B ) after renal I/R ( n = 6). ( C - D ) Representative blots ( C ) and statistical analysis ( D ) of IL-33 protein expression levels in renal tissues after I/R ( n = 6). ( E - F ) Representative images ( E ) and statistical analysis ( F ) of IL-33 immunohistochemistry in renal tissues after I/R ( n = 6). Scale bar was 50 μm. ( G - H ) IL-33 expression and distribution among the groups (blue staining indicate DAPI for nuclei), IL-33 (red) and CD31 (green) ( n = 6). Scale bar was 50 μm. (I-J) Serum MPO-DNA (I) and citH3 levels ( J ) following renal I/R ( n = 6). ( K - L ) Representative blots ( K ) and statistical analysis ( L ) of citH3 protein expression levels in renal tissues after I/R ( n = 6). ( M - N ) NET formation in in the indicated groups (blue indicate DAPI staining), MPO (red) and citH3 (green) ( n = 6). Scale bar was 20 μm. ns no significance, * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: Mice were intraperitoneally injected with recombinant IL-33 (rIL-33) (10ug per mouse, MedChemExpress, America) or PBS immediately following exposure to renal ischemia.

Techniques: Expressing, Immunohistochemistry, Staining

Journal: Inflammation

Article Title: Interleukin-33 Promotes Neutrophil Extracellular Trap Formation To Aggravate Renal Ischemia-Reperfusion Injury Through ST2/PI3K/Akt and ST2/PAD4 Pathways

doi: 10.1007/s10753-025-02364-8

Figure Lengend Snippet: IL-33 promoted NET generation during renal IRI. ( A ) A diagram showing WT mice receiving renal IRI or sham surgery following intraperitoneal injection of rIL-33 (10 µg per mouse) or vehicle (PBS). ( B - C ) Serum MPO-DNA ( B ) and citH3 levels ( C ) of mice in each group ( n = 6). ( D - E ) Representative blots ( D ) and statistical analyses ( E ) of citH3 protein expression levels in renal tissues in the indicated groups ( n = 6). ( F - G ) NET formation in the indicated groups through DAPI staining (blue), MPO (red) and citH3 (green) ( n = 6). Scale bar was 20 μm. ( H - I ) Serum Cr ( H ) and BUN levels ( I ) in the indicated groups ( n = 6). ( J - K ) Representative blots ( J ) and statistical analysis ( K ) of KIM-1 protein expression levels in renal tissues in the indicated groups ( n = 6). ( L - N ) Renal tissues from mice in the indicated groups stained with HE and KIM-1 ( L ), followed by score of tubular injury ( M ) and quantitative analysis of KIM-1 ( N ) ( n = 6). Scale bar was 50 μm. * P < 0.05, ** P < 0.01

Article Snippet: Mice were intraperitoneally injected with recombinant IL-33 (rIL-33) (10ug per mouse, MedChemExpress, America) or PBS immediately following exposure to renal ischemia.

Techniques: Injection, Expressing, Staining

Journal: Inflammation

Article Title: Interleukin-33 Promotes Neutrophil Extracellular Trap Formation To Aggravate Renal Ischemia-Reperfusion Injury Through ST2/PI3K/Akt and ST2/PAD4 Pathways

doi: 10.1007/s10753-025-02364-8

Figure Lengend Snippet: IL-33 exacerbated renal IRI by inducing NET formation. ( A ) A diagram showing the time node of intraperitoneal injection of GSK484 (4 mg/kg) and rIL-33 (10 µg per mouse) in WT mice before renal I/R. (B-C) Serum MPO-DNA ( B ) and citH3 levels ( C ) in the indicated groups ( n = 6). ( D - E ) Representative blots ( D ) and statistical analysis ( E ) of citH3 expression levels in renal tissues of the indicated groups ( n = 6). ( F - G ) NET formation in the indicated groups as determined using the DAPI (blue), MPO (red) and citH3 (green) staining ( n = 6). Scale bar was 20 μm. ( H - I ) Serum Cr ( H ) and BUN levels ( I ) in the indicated groups ( n = 6). ( J - K ) Representative blots ( J ) and statistical analysis ( K ) of KIM-1 protein expression levels in renal tissues from the indicated groups ( n = 6). ( L - N ) Renal tissues of mice in the indicated groups stained with HE and KIM-1 ( L ), followed by score of tubular injury ( M ) and quantitative analysis of KIM-1 ( N ) ( n = 6). Scale bar was 50 μm. ** P < 0.01, *** P < 0.001

Article Snippet: Mice were intraperitoneally injected with recombinant IL-33 (rIL-33) (10ug per mouse, MedChemExpress, America) or PBS immediately following exposure to renal ischemia.

Techniques: Injection, Expressing, Staining

Journal: Inflammation

Article Title: Interleukin-33 Promotes Neutrophil Extracellular Trap Formation To Aggravate Renal Ischemia-Reperfusion Injury Through ST2/PI3K/Akt and ST2/PAD4 Pathways

doi: 10.1007/s10753-025-02364-8

Figure Lengend Snippet: Blocking IL-33 improved renal IRI by reducing NET formation. ( A ) The diagram of WT mice receiving renal IRI or sham surgery after intraperitoneal injection of anti-IL-33 monoclonal antibody (Anti-IL-33) (10 µg per ounce) or vehicle (IgG2b Isotype Control). ( B - C ) Serum MPO-DNA ( B ) and citH3 levels ( C ) of mice in the indicated groups ( n = 6). (D-E) Representative blots ( D ) and statistical analysis ( E ) of citH3 protein expression levels in renal tissues in the indicated groups ( n = 6). ( F - G ) NET formation in the indicated groups following DAPI (blue), MPO (red) and citH3 (green) staining ( n = 6). Scale bar was 20 μm. ( H - I ) Serum Cr ( H ) and BUN levels ( I ) in the indicated group ( n = 6). ( J - K ) Representative blots ( J ) and statistical analysis ( K ) of KIM-1 protein expression levels in renal tissues in the indicated groups ( n = 6). ( L - N ) Renal tissues of mice in the indicated groups subjected to HE and KIM-1 staining ( L ), followed by score of tubular injury ( M ) and statistical analysis of KIM-1 ( N ) ( n = 6). Scale bar was 50 μm. ** P < 0.01, *** P < 0.001

Article Snippet: Mice were intraperitoneally injected with recombinant IL-33 (rIL-33) (10ug per mouse, MedChemExpress, America) or PBS immediately following exposure to renal ischemia.

Techniques: Blocking Assay, Injection, Control, Expressing, Staining

Journal: Inflammation

Article Title: Interleukin-33 Promotes Neutrophil Extracellular Trap Formation To Aggravate Renal Ischemia-Reperfusion Injury Through ST2/PI3K/Akt and ST2/PAD4 Pathways

doi: 10.1007/s10753-025-02364-8

Figure Lengend Snippet: IL-33 stimulated NET generation in vitro. ( A - B ) Neutrophils incubated with PBS, PMA (100nM) and various concentrations of rIL-33 (20, 60, 100 ng/mL) for 4 h. rIL-33 stimulation increased MPO-DNA ( A ) and citH3 levels ( B ) in the neutrophil culture medium in a dose-dependent manner relative to the PBS group ( n = 3). ( C - D ) Relative to the PBS group, rIL-33 activated neutrophils to increase citH3 protein in a dose-dependent manner ( n = 3). ( E ) Compared with the PBS group, rIL-33 increased the expression of ST2 mRNA on neutrophils ( n = 3). ( F ) Representative scanning electron microscopy graphs of neutrophils treated with PBS or rIL-33 (100ng/mL) for 4 h. Scale bar was 10 μm. ( G ) The NET formation as indicated by DAPI (blue), MPO (red) and citH3 (green) staining, was comparable between rIL-33 (100ng/mL) and PMA group. Scale bar was 50 μm. ns no significance, * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: Mice were intraperitoneally injected with recombinant IL-33 (rIL-33) (10ug per mouse, MedChemExpress, America) or PBS immediately following exposure to renal ischemia.

Techniques: In Vitro, Incubation, Expressing, Electron Microscopy, Staining

Journal: Inflammation

Article Title: Interleukin-33 Promotes Neutrophil Extracellular Trap Formation To Aggravate Renal Ischemia-Reperfusion Injury Through ST2/PI3K/Akt and ST2/PAD4 Pathways

doi: 10.1007/s10753-025-02364-8

Figure Lengend Snippet: IL-33 induced NET formation via ST2/PI3K/Akt and ST2/PAD4 signaling pathways. Mouse bone marrow-derived neutrophils were treated with PBS or rIL-33 (100ng/mL) for 4 h, followed by RNA sequencing ( n = 3). ( A - B ) Volcano plot ( A ) and heatmap ( B ) showing differential gene expression between PBS and rIL-33 groups. ( C ) GO enrichment analysis of DEGs. ( D ) KEGG pathway enrichment analysis of DEGs. Bone marrow-derived neutrophils from WT and ST2 KO mice were treated with PBS or rIL-33 (100ng/mL) for 4 h. The production of MPO-DNA ( E ) and citH3 ( F ) in the cell culture medium of ST2 KO neutrophils treated with IL-33 was markedly decreased relative to the IL-33-treated WT neutrophils ( n = 3). ( G ) Confocal microscopy was conducted to examine NET formation (co-localization of DAPI, MPO and citH3) in each group. ( H - I ) The expression of PI3K, p-PI3K, Akt, p-Akt and citH3 in WT and ST2 KO neutrophils stimulated by rIL-33 as determined by Western blot ( n = 3). ( J - K ) WT neutrophils were treated with 10µM LY294002 (PI3K inhibitor) or 10µM MK2206 (Akt inhibitor) for 24 h, and 100ng/mL rIL-33 was added on the 20th h to stimulate WT neutrophils for 4 h. The expression of PI3K, p-PI3K, Akt, p-Akt and citH3 in neutrophils was determined by Western blot ( n = 3). ( L ) Gene expression of Padi1, Padi2, Padi4 and Padi6 in neutrophils stimulated with rIL-33 ( n = 3). The gene expression data were expressed as log 2 (FPKM + 1). ( M - N ) PAD4 protein expression levels and quantitative analysis in WT and ST2 KO neutrophils treated with rIL-33 were quantified by Western blots ( n = 3). ( O - P ) WT neutrophils were pretreated with GSK484 (PAD4 inhibitor) for 30 min after treatment with 100ng/mL rIL-33 for 4 h. The protein expression of citH3 in neutrophils was determined by Western blot ( n = 3). ns no significance, * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: Mice were intraperitoneally injected with recombinant IL-33 (rIL-33) (10ug per mouse, MedChemExpress, America) or PBS immediately following exposure to renal ischemia.

Techniques: Protein-Protein interactions, Derivative Assay, RNA Sequencing, Gene Expression, Cell Culture, Confocal Microscopy, Expressing, Western Blot

Journal: Inflammation

Article Title: Interleukin-33 Promotes Neutrophil Extracellular Trap Formation To Aggravate Renal Ischemia-Reperfusion Injury Through ST2/PI3K/Akt and ST2/PAD4 Pathways

doi: 10.1007/s10753-025-02364-8

Figure Lengend Snippet: Schematic diagram of the mechanism by which IL-33 exacerbated renal IRI by enhancing NET formation during renal I/R

Article Snippet: Mice were intraperitoneally injected with recombinant IL-33 (rIL-33) (10ug per mouse, MedChemExpress, America) or PBS immediately following exposure to renal ischemia.

Techniques:

Journal: bioRxiv

Article Title: Primary lung fibroblasts respond to IL-33, IL-13, and IL-17A by secreting factors that activate macrophages

doi: 10.1101/2023.02.28.530495

Figure Lengend Snippet:

Article Snippet: Recombinant (r) mouse cytokines were purchased from BioLegend: rIL-33 (580502), rIL- 13 (575904), rIL-17A (576002).

Techniques: In Vitro, Recombinant, Enzyme-linked Immunosorbent Assay

Journal: bioRxiv

Article Title: Primary lung fibroblasts respond to IL-33, IL-13, and IL-17A by secreting factors that activate macrophages

doi: 10.1101/2023.02.28.530495

Figure Lengend Snippet: Transcriptomic analysis of alveolar macrophages treated with combinations of recombinant IL-33, IL-13, and IL-17A in vitro . Macrophages were extracted from wild-type (WT) BALB/cJ mice as described in Methods and were plated in technical triplicate for whole transcriptomic sequencing. ( A ) Principal Component Analysis was used for assessing global, transcriptional changes induced by combinations of recombinant (r) IL-33, rIL-13, and rIL-17A in alveolar macrophages. ( B ) Volcano plot of differentially expressed genes between rIL-13-treated and control alveolar macrophages. Significance cut-offs for this analysis was designated to be p-value <.0001, fold change = +/- 1.5. Gene identifiers were manually annotated and therefore approximated. For volcano plots, the X-axis was transformed as a function of Log2[fold-change], whereas the Y-axis was generated by calculating -log10[p-value]. ( C ) Scatter plots designating expression levels of Il17ra and Il17rc in alveolar macrophages at baseline and post-cytokine stimulation (TPM-normalized). Bulk RNA sequencing of alveolar macrophages stimulated in vitro was performed only once.

Article Snippet: Recombinant (r) mouse cytokines were purchased from BioLegend: rIL-33 (580502), rIL- 13 (575904), rIL-17A (576002).

Techniques: Recombinant, In Vitro, Sequencing, Transformation Assay, Generated, Expressing, RNA Sequencing Assay

Journal: bioRxiv

Article Title: Primary lung fibroblasts respond to IL-33, IL-13, and IL-17A by secreting factors that activate macrophages

doi: 10.1101/2023.02.28.530495

Figure Lengend Snippet: Extended transcriptional analysis of alveolar macrophages treated with combinations of recombinant IL-33, IL-13, and IL-17A relative to baseline. The algorithm DESeq2 was applied for identifying and ranking the significance of genes differentially expressed between macrophage treatment groups. DESeq2 computed an ANOVA table (fold-change, p-value, false-discovery rate step-up) for each comparison visualized here. Significantly up- or downregulated genes were illustrated by volcano plot once transformed as function of -log10[p-value] (Y-axis) and Log2[fold-change] (X-axis). Normalization of the data (median ratio) was also performed with DESeq2 by default. Significance cut-offs for this analysis was designated to be p-value <.0001, fold change = +/- 1.5. Gene identifiers in each visualization were manually annotated, and some lines are thus approximated due to size restraints and overlapping of datapoints.

Article Snippet: Recombinant (r) mouse cytokines were purchased from BioLegend: rIL-33 (580502), rIL- 13 (575904), rIL-17A (576002).

Techniques: Recombinant, Comparison, Transformation Assay

Journal: bioRxiv

Article Title: Primary lung fibroblasts respond to IL-33, IL-13, and IL-17A by secreting factors that activate macrophages

doi: 10.1101/2023.02.28.530495

Figure Lengend Snippet: GM-CSF production by primary lung fibroblasts induced by combinations of recombinant IL-33, IL-13, and IL-17A ( A ) Lung fibroblasts first were passaged 3 to 5 times and then plated in quadruplicate for preliminary stimulation assays, as described in Methods . ( B ) Levels of GM-CSF (pg/ml) secreted into the culture supernatant by wild-type (WT) primary lung fibroblasts treated with combinations of recombinant (r) IL-33, rIL-13, and rIL-17A. ( C ) Levels of GM-CSF (pg/ml) secreted into the culture supernatant by WT and St2 -/- fibroblasts treated with rIL-33/rIL-13a/rIL-17A in vitro . Significance ( p-value < .05 ) was determined with ordinary one-way ( B ) or two-way ANOVA ( C ). Multiple comparison testing was computed post-hoc, and p-values were calculated without mathematical correction using the unprotected Fischer’s Least Significant Difference test. ( B ) rIL- 33/rIL-13/rIL-17A vs. untreated, p <0.0001 ; rIL-33/rIL-17A vs. untreated, p =0.0271 ; rIL-33/rIL-13, p =0.0359 . ( C ) WT, p <0.0001 ; St2 -/- , p =0.0878. Experiments for ( B ) and ( C ) were performed at least twice, yielding similar outcomes.

Article Snippet: Recombinant (r) mouse cytokines were purchased from BioLegend: rIL-33 (580502), rIL- 13 (575904), rIL-17A (576002).

Techniques: Recombinant, In Vitro, Comparison

Journal: bioRxiv

Article Title: Primary lung fibroblasts respond to IL-33, IL-13, and IL-17A by secreting factors that activate macrophages

doi: 10.1101/2023.02.28.530495

Figure Lengend Snippet: Whole transcriptomic analysis of primary lung fibroblasts treated with combinations of recombinant IL-33, IL-13, and IL-17A in vitro . Fibroblasts were cultured and stimulated in triplicate with combinations of cytokines, as described in the Methods . ( A ) Principal component analysis of the transcriptional changes induced by four cytokine combinations in vitro . ( B ) Csf2 expression in primary lung fibroblasts determined by RNAseq and illustrated by scatter plot (TPM-normalized). ( C-F ) Volcano plots showing differential gene expression of cells treated with recombinant (r) cytokines versus untreated fibroblasts; ( C ) rIL-33/rIL-13/rIL-17A, ( D ) rIL-33/13 , ( E ) rIL-33/17A , ( F ) rIL-33 vs. untreated . Significance cut-offs for this analysis was designated to be p-value <.0001, fold change +/- 1.5. Gene identifiers in each volcano plot were manually annotated and therefore approximated. For generating volcano plots, data were transformed as function of -log10[p- value] (Y-axis) and Log2[fold-change] (X-axis). ( G ) Gene Set Enrichment (GO analysis) of the top 238 differentially expressed genes identified in triple-treated cells. Bulk RNA sequencing of primary lung fibroblasts stimulated in vitro was performed only once.

Article Snippet: Recombinant (r) mouse cytokines were purchased from BioLegend: rIL-33 (580502), rIL- 13 (575904), rIL-17A (576002).

Techniques: Recombinant, In Vitro, Cell Culture, Expressing, Transformation Assay, RNA Sequencing Assay

Journal: bioRxiv

Article Title: Primary lung fibroblasts respond to IL-33, IL-13, and IL-17A by secreting factors that activate macrophages

doi: 10.1101/2023.02.28.530495

Figure Lengend Snippet: Significantly upregulated and downregulated gene expression in lung fibroblasts after rIL-33/rIL-13/rIL-17A treatment. Statistically significant (p<.0001), differential expression (fold change +/- 1.5) was noted initially for 1,642 genes (among the 18,079 detected by RNAseq) when comparing rIL- 33/13/17A-stimulated fibroblasts to untreated cells (refer to ). We extended our comparative analysis by identifying statistically significant, differentially expressed genes in rIL- 33/13/17A-stimulated fibroblasts relative to every group that received cytokine treatment during the assay ( i.e., vs. rIL-33/rIL-13, rIL-33/rIL-17A- and rIL-33-stimulated fibroblasts). From the original list of 1,642 genes (rIL-33/rIL-13/rIL-17A-stimulated fibroblasts vs. untreated), only 268 genes were statistically significant upon comparing rIL-33/rIL-13/rIL-17A cells to each remaining treatment group (false discovery rate <.01; 131 downregulated and 137 upregulated). Ultimately, we ranked gene expression in this filtered ANOVA table using the fold-change value derived from comparing rIL-33/rIL-13/rIL-17A-stimulated fibroblasts to untreated cells.

Article Snippet: Recombinant (r) mouse cytokines were purchased from BioLegend: rIL-33 (580502), rIL- 13 (575904), rIL-17A (576002).

Techniques: Expressing, Derivative Assay

Journal: bioRxiv

Article Title: Primary lung fibroblasts respond to IL-33, IL-13, and IL-17A by secreting factors that activate macrophages

doi: 10.1101/2023.02.28.530495

Figure Lengend Snippet: Fibroblasts were isolated from digested whole lung, whereas macrophages (BMDM) were derived in vitro from monocytes extracted from the bone marrow. ( A ) Independent cultures of fibroblasts were subjected to cytokine treatment, but for the purpose of harvesting fibroblast- conditioned media (FCM) that can be transferred to BMDM cultures. Activation phenotypes for BMDM were assessed by RT-qPCR. ( B ) Induction of Arg1 expression in BMDM cultures activated by FCM. ( C ) Induction of Arg1 expression in BMDM cultures treated with cytokine cocktails containing rIL-13. ( B-C ) Significance ( p-value < .05 ) was determined with ordinary one-way ANOVA. Multiple comparison testing was computed post-hoc, and p-values were calculated without mathematical correction using the unprotected Fischer’s Least Significant Difference test. ( B ) rIL-33/rIL-13/rIL-17A FCM vs. untreated FCM, p <0.0001 ; rIL-33/rIL-13 FCM vs. untreated FCM, p <0.0001 ; rIL-33/rIL-17A FCM vs. untreated FCM, p <0.0001 . ( C ) rIL-13 vs. rIL-33/rIL-13/rIL-17A, p =0.2289. ( B-C ) Data representative of an experiment performed at least twice, yielding comparable outcomes.

Article Snippet: Recombinant (r) mouse cytokines were purchased from BioLegend: rIL-33 (580502), rIL- 13 (575904), rIL-17A (576002).

Techniques: Isolation, Derivative Assay, In Vitro, Activation Assay, Quantitative RT-PCR, Expressing, Comparison

Journal: bioRxiv

Article Title: Primary lung fibroblasts respond to IL-33, IL-13, and IL-17A by secreting factors that activate macrophages

doi: 10.1101/2023.02.28.530495

Figure Lengend Snippet: Gene and protein expression in BMDM generated for in vitro use. BMDM were cultured as described in Methods . ( A-B ) Retnla and Ym1 gene expression was measured in FCM-treated BMDM at least once as part of work for supporting Arg1 induction in these cells (refer to ). There was no desire to replicate qPCR for Ym1 and Retnla because nominal changes were detected upon first trial, despite normal and interpretable exponentiation of housekeeping genes assayed at the same time. ( C ) In at least one of three, conventional M2 assays performed for this work (refer to ), Retnla was measured in BMDM treated with cytokines rIL-13 or rIL-33/rIL-33/rIL-17A directly. Significance (p-value < . 05 ) was determined with ordinary one-way ANOVA. Multiple comparison testing was computed post-hoc, and p-values were calculated without mathematical correction using the unprotected Fischer’s Least Significant Difference test. ( A ) rIL-33/rIL-13/rIL-17A FCM vs. untreated FCM, p =0.1984; rIL-33 vs. untreated FCM, p = 0.0101 . ( B ) ns = not significant. ( C ) rIL-13 vs. rIL-33/rIL- 13/rIL-17A, p =0.0066 . ( D ) Surface protein expression measured by flow cytometry, having stained BMDM with anti-CD11b-BV785 and anti-Csf2ra-Alexa Flour 700. Positive signal for each protein was gated by comparing sample directly to a FMO control. Acquisition was performed on an LSR-II (Becton Dickinson, Franklin Lakes NJ). Cytometry of WT BMDM was performed twice and in technical triplicate.

Article Snippet: Recombinant (r) mouse cytokines were purchased from BioLegend: rIL-33 (580502), rIL- 13 (575904), rIL-17A (576002).

Techniques: Expressing, Generated, In Vitro, Cell Culture, Comparison, Flow Cytometry, Staining, Cytometry